These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Probiotics for induction of remission in ulcerative colitis. Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795 [TBL] [Abstract][Full Text] [Related]
23. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. Tindall WN; Boltri JM; Wilhelm SM J Manag Care Pharm; 2007 Sep; 13(7 Suppl A):S2-12; quiz S13-4. PubMed ID: 17874873 [TBL] [Abstract][Full Text] [Related]
24. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B; Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596 [TBL] [Abstract][Full Text] [Related]
25. Newer pharmacologic agents for the therapy of inflammatory bowel disease. Ruderman WB Med Clin North Am; 1990 Jan; 74(1):133-53. PubMed ID: 2404172 [TBL] [Abstract][Full Text] [Related]
27. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Singh S; Kim J; Zhu W; Dulai PS; Sandborn WJ; Jairath V Aliment Pharmacol Ther; 2020 Aug; 52(3):481-491. PubMed ID: 32573825 [TBL] [Abstract][Full Text] [Related]
28. Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Report and Review of the Literature. Ali NM; Shehab MA Am J Case Rep; 2023 Nov; 24():e940966. PubMed ID: 37926993 [TBL] [Abstract][Full Text] [Related]
31. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ Cochrane Database Syst Rev; 2012 Nov; 11():CD004118. PubMed ID: 23152224 [TBL] [Abstract][Full Text] [Related]
32. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A Patient; 2012; 5(1):33-44. PubMed ID: 22077619 [TBL] [Abstract][Full Text] [Related]
33. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Hu MY; Peppercorn MA Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346 [TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650 [TBL] [Abstract][Full Text] [Related]
35. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry. Calafat M; Torres P; Tosca-Cuquerella J; Sánchez-Aldehuelo R; Rivero M; Iborra M; González-Vivo M; Vera I; de Castro L; Bujanda L; Barreiro-de Acosta M; González-Muñoza C; Calvet X; Benítez JM; Llorente-Barrio M; Surís G; Cañete F; Arias-García L; Monfort D; Castaño-García A; Garcia-Alonso FJ; Huguet JM; Marín-Jímenez I; Lorente R; Martín-Cardona A; Ferrer JÁ; Camo P; Gisbert JP; Pajares R; Gomollón F; Castro-Poceiro J; Morales-Alvarado J; Llaó J; Rodríguez A; Rodríguez C; Pérez-Galindo P; Navarro M; Jiménez-García N; Carrillo-Palau M; Blázquez-Gómez I; Sesé E; Almela P; Ramírez de la Piscina P; Taxonera C; Rodríguez-Lago I; Cabrinety L; Vela M; Mínguez M; Mesonero F; García MJ; Aguas M; Márquez L; Silva Porto M; Pineda JR; García-Etxebarría K; Bertoletti F; Brunet E; Mañosa M; Domènech E Therap Adv Gastroenterol; 2024; 17():17562848231221713. PubMed ID: 38187926 [TBL] [Abstract][Full Text] [Related]
36. Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN. Atia O; Magen Rimon R; Ledderman N; Greenfeld S; Kariv R; Loewenberg Weisband Y; Shaoul R; Matz E; Odes S; Goren I; Yanai H; Dotan I; Turner D Inflamm Bowel Dis; 2024 Feb; 30(2):213-221. PubMed ID: 37084279 [TBL] [Abstract][Full Text] [Related]
37. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis. Cichewicz A; Tencer T; Gupte-Singh K; Egodage S; Burnett H; Kumar J Adv Ther; 2023 May; 40(5):2116-2146. PubMed ID: 37000363 [TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review. Santos Y; Jaramillo AP Cureus; 2023 Aug; 15(8):e44055. PubMed ID: 37638277 [TBL] [Abstract][Full Text] [Related]
39. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. Coates E; Wickramasekera N; Barr A; Shackley P; Lee M; Hind D; Probert C; Sebastian S; Totton N; Blackwell S; Bedford H; Dames N; Lobo A Health Technol Assess; 2022 Oct; 26(41):1-118. PubMed ID: 36305390 [TBL] [Abstract][Full Text] [Related]
40. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Berends SE; Strik AS; Löwenberg M; D'Haens GR; Mathôt RAA Clin Pharmacokinet; 2019 Jan; 58(1):15-37. PubMed ID: 29752633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]